BACKGROUND: The extent of lymphadenectomy needed to optimize oncologic outcomes after radical cystectomy (RC) for patients with regionally advanced bladder cancer (BCa) is unclear. OBJECTIVE: Evaluate the effect of the location of lymph node metastasis on recurrence-free survival (RFS) and cancer-specific survival (CSS) for patients undergoing RC with a mapping pelvic lymph node dissection (PLND). DESIGN, SETTING, AND PARTICIPANTS: A study of 591 patients undergoing RC with mapping PLND was completed between 2000 and 2010. Median follow-up was 30 mo. INTERVENTION: RC with mapping PLND. MEASUREMENTS: We evaluated the impact of lymph node involvement by location on disease outcomes using the 2010 TNM staging system. Survival estimates were described using Kaplan-Meier methods. Gender, age, pathologic stage, histology, number of positive nodes, location of positive nodes, node density, use of perioperative chemotherapy, and grade were evaluated as predictors of RFS and CSS using multivariate Cox proportional hazard regression. RESULTS AND LIMITATIONS: Overall, 114 patients (19%) had lymph node involvement, and 42 patients (7%) had pN3 disease. On multivariate analysis, the number of positive lymph nodes (one or two or more) was significantly associated with increased risk of cancer-specific death (hazard ratio [HR]: 1.9 [95% confidence interval (CI), 1.04-3.46], p=0.036; versus HR: 4.3 [95% CI, 2.25-8.34], p<0.0005). Positive lymph node location was not an independent predictor of RFS or CSS. Five-year RFS for pN3 patients undergoing RC with PLND was 25% (95% CI, 10-42). This finding was not statistically different from our pN1 and pN2 patients (38% [95% CI, 22-54] and 35% [95% CI, 11-60], respectively). This study is limited by the lack of prospective randomization and a control group. CONCLUSIONS: The outcome for patients with involved common iliac lymph nodes was similar to the outcome for patients with primary nodal basin disease. These data support inclusion of the common iliac lymph nodes (pN3) in the nodal staging system for BCa. Lymph node location was not an independent predictor of outcome, whereas the number of positive lymph nodes was an independent predictor of worse oncologic outcome (pN1, pN2). Further refinements of the TNM system to provide improved prognostication are warranted.
BACKGROUND: The extent of lymphadenectomy needed to optimize oncologic outcomes after radical cystectomy (RC) for patients with regionally advanced bladder cancer (BCa) is unclear. OBJECTIVE: Evaluate the effect of the location of lymph node metastasis on recurrence-free survival (RFS) and cancer-specific survival (CSS) for patients undergoing RC with a mapping pelvic lymph node dissection (PLND). DESIGN, SETTING, AND PARTICIPANTS: A study of 591 patients undergoing RC with mapping PLND was completed between 2000 and 2010. Median follow-up was 30 mo. INTERVENTION: RC with mapping PLND. MEASUREMENTS: We evaluated the impact of lymph node involvement by location on disease outcomes using the 2010 TNM staging system. Survival estimates were described using Kaplan-Meier methods. Gender, age, pathologic stage, histology, number of positive nodes, location of positive nodes, node density, use of perioperative chemotherapy, and grade were evaluated as predictors of RFS and CSS using multivariate Cox proportional hazard regression. RESULTS AND LIMITATIONS: Overall, 114 patients (19%) had lymph node involvement, and 42 patients (7%) had pN3 disease. On multivariate analysis, the number of positive lymph nodes (one or two or more) was significantly associated with increased risk of cancer-specific death (hazard ratio [HR]: 1.9 [95% confidence interval (CI), 1.04-3.46], p=0.036; versus HR: 4.3 [95% CI, 2.25-8.34], p<0.0005). Positive lymph node location was not an independent predictor of RFS or CSS. Five-year RFS for pN3patients undergoing RC with PLND was 25% (95% CI, 10-42). This finding was not statistically different from our pN1 and pN2patients (38% [95% CI, 22-54] and 35% [95% CI, 11-60], respectively). This study is limited by the lack of prospective randomization and a control group. CONCLUSIONS: The outcome for patients with involved common iliac lymph nodes was similar to the outcome for patients with primary nodal basin disease. These data support inclusion of the common iliac lymph nodes (pN3) in the nodal staging system for BCa. Lymph node location was not an independent predictor of outcome, whereas the number of positive lymph nodes was an independent predictor of worse oncologic outcome (pN1, pN2). Further refinements of the TNM system to provide improved prognostication are warranted.
Authors: J Leissner; M A Ghoneim; H Abol-Enein; J W Thüroff; L Franzaring; M Fisch; H Schulze; G Managadze; E P Allhoff; M A el-Baz; H Kastendieck; P Buhtz; S Kropf; R Hohenfellner; H K Wolf Journal: J Urol Date: 2004-01 Impact factor: 7.450
Authors: Harry W Herr; James R Faulkner; H Barton Grossman; Ronald B Natale; Ralph deVere White; Michael F Sarosdy; E David Crawford Journal: J Clin Oncol Date: 2004-06-15 Impact factor: 44.544
Authors: H Barton Grossman; Ronald B Natale; Catherine M Tangen; V O Speights; Nicholas J Vogelzang; Donald L Trump; Ralph W deVere White; Michael F Sarosdy; David P Wood; Derek Raghavan; E David Crawford Journal: N Engl J Med Date: 2003-08-28 Impact factor: 91.245
Authors: Bernard H Bochner; Daniel Cho; Harry W Herr; Machele Donat; Michael W Kattan; Guido Dalbagni Journal: J Urol Date: 2004-10 Impact factor: 7.450
Authors: Nivedita Bhatta Dhar; Eric A Klein; Alwyn M Reuther; George N Thalmann; Stephan Madersbacher; Urs E Studer Journal: J Urol Date: 2008-01-25 Impact factor: 7.450
Authors: Michael J Metcalfe; James E Ferguson; Roger Li; Lianchun Xiao; Charles C Guo; Bogdan A Czerniak; Arlene Siefker-Radtke; Shanna M Pretzsch; Neema Navai; David J McConkey; Ashish M Kamat; Mathew Campbell; Colin Dinney Journal: Eur Urol Focus Date: 2017-07-13
Authors: M May; C Protzel; M W Vetterlein; M Gierth; J Noldus; A Karl; T Grimm; B Wullich; M O Grimm; P Nuhn; P J Bastian; J Roigas; B Hadaschik; C Gilfrich; M Burger; M Fisch; S Brookman-May; A Aziz; O W Hakenberg Journal: Int Urol Nephrol Date: 2016-11-28 Impact factor: 2.370
Authors: Ahmed A Hussein; Nobuyuki Hinata; Shiva Dibaj; Paul R May; Justen D Kozlowski; Hassan Abol-Enein; Ronney Abaza; Daniel Eun; Mohamed S Khan; James L Mohler; Piyush Agarwal; Kamal Pohar; Richard Sarle; Ronald Boris; Sridhar S Mane; Alan Hutson; Khurshid A Guru Journal: BJU Int Date: 2017-01-18 Impact factor: 5.588
Authors: Lars Weisbach; Roland Dahlem; Giuseppe Simone; Jens Hansen; Armin Soave; Oliver Engel; Felix K Chun; Shahrokh F Shariat; Margit Fisch; Michael Rink Journal: Int Urol Nephrol Date: 2013-07-25 Impact factor: 2.370
Authors: Timur Mitin; Daniel Hunt; William U Shipley; Donald S Kaufman; Robert Uzzo; Chin-Lee Wu; Mark K Buyyounouski; Howard Sandler; Anthony L Zietman Journal: Lancet Oncol Date: 2013-07-01 Impact factor: 41.316
Authors: Jeremy W Martin; Simone L Vernez; Yair Lotan; Ahmed Abdelhalim; Rahul Dutta; Ahmed Shokeir; Hassan Abol-Enein; Ahmed Mosbah; Mohamed Ghoneim; Ramy F Youssef Journal: World J Urol Date: 2018-05-14 Impact factor: 4.226